NCE-1 Intelligence & Market Opportunity

Romvimza

Vimseltinib

Anticancer

Oral Capsule

Romvimza is a tablet for adults with tenosynovial giant cell tumor when surgery might worsen joint function. It blocks CSF-1R to shrink tumors and ease symptoms.

Approval Date

14-Feb-25

NCE-1 Date

14-Feb-29

NCE Date

14-Feb-30

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

36.87%

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

124

2028

156

2029

186

2030

215

2031

243

2032

264

Molecule profile

Details & specifications

Molecule

Vimseltinib

Innovator

DECIPHERA PHARMACEUTICALS LLC

Dosage Form

Oral Capsule

Strength

14 mg, 20 mg and 30 mg

Therapeutic Category

Anticancer

Usage

To treat symptomatic tenosynovial giant cell tumor for which surgical resection will potentially cause worsening functional limitation or severe morbidity

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets